Primary Site >> Pancreatic Cancer
Gene >> NELFCD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Antitumor effect of human pancreatic cancer cells transduced with cytokine genes which activate Th1 helper T cells. PMID: 9568099 |
Ref: Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. PMID: 10433946 Ref: Immunoregulation in pancreatic cancer patients. PMID: 10478644 |
Ref: Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma. PMID: 10976976 |
Ref: Differential and mutually exclusive expression of CD95 and CD95 ligand in epithelia of normal pancreas and chronic pancreatitis. PMID: 11310825 |
Ref: Progression or resolution of coxsackievirus B4-induced pancreatitis: a genomic analysis. PMID: 15254194 Ref: [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer]. PMID: 15553672 |
Ref: High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. PMID: 16267034 |
Ref: Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology. PMID: 16914584 Ref: [Immunotherapeutic effects of beta-elemene combined with interleukin-23 gene-modified dendritic cells on murine pancreatic carcinoma]. PMID: 16965646 |
Ref: Immunotherapeutic effects on murine pancreatic carcinoma by beta-elemene combined with dendritic cells modified with genes encoding interleukin-23. PMID: 24557615 |
Ref: Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. PMID: 18941250 |
Ref: Genetic determined downregulation of both type 1 and type 2 cytokine pathways might be protective against pancreatic cancer. PMID: 19250218 Ref: Advanced stomach and pancreas cancer successfully treated with combination chemotherapy with S-1/paclitaxel/lentinan. PMID: 19453038 Ref: Th1 and Th2 profiles in patients with pancreatic cancer compared with chronic pancreatitis. PMID: 19550277 Ref: Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. PMID: 19578774 Ref: Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. PMID: 19738045 Ref: Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. PMID: 19798410 |
Ref: Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. PMID: 21339327 Ref: Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. PMID: 21551368 Ref: The presence of Helicobacter pylori in the liver depends on the Th1, Th17 and Treg cytokine profile of the patient. PMID: 22012231 |
Ref: High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. PMID: 21780106 Ref: Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. PMID: 22523087 Ref: Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer. PMID: 22720220 |
Ref: Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway. PMID: 23394575 Ref: Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. PMID: 23640603 Ref: Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. PMID: 24209604 Ref: Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice. PMID: 25198660 |
Ref: Embelin suppresses pancreatic cancer growth by modulating tumor immune microenvironment. PMID: 24389175 Ref: Research on the epigenetic modification of pancreatic cancer vaccine. PMID: 24901123 Ref: Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. PMID: 24919654 Ref: Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. PMID: 25941601 |
Ref: Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. PMID: 25725585 Ref: Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. PMID: 25942397 Ref: A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination. PMID: 26405163 |
Ref: Dendritic cell-based vaccine for pancreatic cancer in Japan. PMID: 26855819 Ref: Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients. PMID: 26873846 Ref: Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. PMID: 26918344 Ref: Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. PMID: 27083074 |
Ref: Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. PMID: 27864347 Ref: Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro. PMID: 28223726 Ref: NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. PMID: 28442553 Ref: Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy. PMID: 28961038 Ref: Apolipoprotein A-I mimetic peptide 4F suppresses tumor-associated macrophages and pancreatic cancer progression. PMID: 29245934 |
Ref: Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival. PMID: 29404962 Ref: Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. PMID: 29409514 Ref: The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. PMID: 29567829 Ref: The Microbiome and Pancreatic Cancer: An Evidence-based Association? PMID: 30001289 Ref: Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. PMID: 30017877 Ref: Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium. PMID: 30035346 Ref: Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine. PMID: 30068705 |